Clinical Trials Logo

HER-2 Negative Breast Cancer clinical trials

View clinical trials related to HER-2 Negative Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05761470 Recruiting - Clinical trials for Her-2 Negative Breast Cancer

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

IMPARP
Start date: May 6, 2022
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.

NCT ID: NCT03799692 Recruiting - Clinical trials for HER-2 Negative Breast Cancer

Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Start date: November 19, 2018
Phase: Phase 4
Study type: Interventional

This is an open-label, single arm, two-stage Simon Design study for women with LuminalB/HER-2 Negative Breast Cancer treated with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin. The primary objective of the trial is to evaluate of the efficacy and safety of Nanoparticle Albumin-Bound Paclitaxel Combined with Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer. The primary endpoint of the study is to assess Pathological complete response rate(pCR)using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The total number of patients to be included in this study is 78 patients. The duration of the study, from first patient visit to last patient visit will be approximately 12 months.